<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113166</article-id><article-id pub-id-type="publisher-id">ACM-41074</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_57773217.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  合并便秘的帕金森病人血清尿酸、同型半胱氨酸水平分析
  Analysis of Serum Uric Acid and Homocysteine Levels in Parkinson’s Patients with Constipation
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邱</surname><given-names>蕊</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>叶</surname><given-names>珊珊</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>雪宁</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郝</surname><given-names>中楠</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>爱军</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>1154</fpage><lpage>1159</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：为研究血清尿酸(UA)、同型半胱氨酸(Hcy)与帕金森病(PD)合并便秘之间的关系。方法：选择从2020年5月~2021年1月于青岛大学附属医院门诊就诊的109例帕金森病，设为PD组，并根据患者现病史描述是否便秘，将PD组分为便秘组与非便秘组。并选取同期在本院105名体检健康者设为对照组。1) 分析血尿酸、血同型半胱氨酸水平与帕金森病的相关性。2) 分析合并RBD的帕金森病患者与这两项血清指标可能的联系。结果：1) PD组与正常对照组相比，两组UA、Hcy水平有差异，差异有统计学意义(P &lt; 0.05)；2) 便秘组与非便秘组UA水平比较差异无统计学意义，便秘组Hcy水平高于非便秘组，差异有统计学意义(P &lt; 0.05)；3) 帕金森病的严重程度与尿酸水平呈负相关，与同型半胱氨酸成正相关，差异有统计学意义(P &lt; 0.05)；4) Hcy对便秘的诊断效能为：(AUC = 0.661, 95% CI = 0.556~0.767, P &lt; 0.05)，其灵敏性和特异性分别为：58.3%，75.4%。结论：血清尿酸、同型半胱氨酸与帕金森病的发病有一定的相关性，且帕金森病病的严重程度与尿酸水平呈负相关，与同型半胱氨酸成正相关。同型半胱氨酸可能成为PD合并便秘的新的生物标志物。
    Objective: To study the relationship between serum uric acid (UA), homocysteine (Hcy) and Parkinson’s disease (PD) combined with constipation. Methods: 109 cases of Parkinson’s disease who were treated in the outpatient clinic of Qingdao University Hospital from May 2020 to January 2021 were selected as the PD group. According to the patient’s current medical history, the PD group was divided into the constipation group and the non-constipation group. And 105 healthy people were selected in our hospital during the same period as the control group. 1) Analyze the correlation between blood uric acid, blood homocysteine levels and Parkinson’s disease. 2) Analyze the possible relationship between these two serum indexes in Parkinson’s disease patients with RBD. Results: 1) Compared with the normal control group, the UA and Hcy levels of the two groups were different in the PD group, and the difference was statistically significant (P &lt; 0.05); 2) There was no significant difference in the UA level between the constipation group and the non-constipation group. The Hcy level of the constipation group was higher than that of the non-constipation group, and the difference was statistically significant (P &lt; 0.05); 3) The severity of Parkinson’s disease was negatively correlated with the level of uric acid, and positively correlated with homocysteine. There was statistical significance (P &lt; 0.05); 4) The diagnostic efficiency of Hcy for constipation is: (AUC = 0.661, 95% CI = 0.556~0.767, P &lt; 0.05), and its sensitivity and specificity are 58.3% and 75.4%, respectively. Conclusion: Serum uric acid and isotype cysteine have a certain correlation with the onset of Parkinson’s disease, and the severity of Parkinson’s disease is negatively correlated with uric acid levels and positively correlated with homocysteine. Homocysteine may become a new biomarker of PD with constipation. 
  
 
</p></abstract><kwd-group><kwd>帕金森病，便秘，尿酸，同型半胱氨酸，生物标志物, Parkinson’s Disease</kwd><kwd> Constipation</kwd><kwd> Uric Acid</kwd><kwd> Homocysteine</kwd><kwd> Biomarkers</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：为研究血清尿酸(UA)、同型半胱氨酸(Hcy)与帕金森病(PD)合并便秘之间的关系。方法：选择从2020年5月~2021年1月于青岛大学附属医院门诊就诊的109例帕金森病，设为PD组，并根据患者现病史描述是否便秘，将PD组分为便秘组与非便秘组。并选取同期在本院105名体检健康者设为对照组。1) 分析血尿酸、血同型半胱氨酸水平与帕金森病的相关性。2) 分析合并RBD的帕金森病患者与这两项血清指标可能的联系。结果：1) PD组与正常对照组相比，两组UA、Hcy水平有差异，差异有统计学意义(P &lt; 0.05)；2) 便秘组与非便秘组UA水平比较差异无统计学意义，便秘组Hcy水平高于非便秘组，差异有统计学意义(P &lt; 0.05)；3) 帕金森病的严重程度与尿酸水平呈负相关，与同型半胱氨酸成正相关，差异有统计学意义(P &lt; 0.05)；4) Hcy对便秘的诊断效能为：(AUC = 0.661, 95% CI = 0.556~0.767, P &lt; 0.05)，其灵敏性和特异性分别为：58.3%，75.4%。结论：血清尿酸、同型半胱氨酸与帕金森病的发病有一定的相关性，且帕金森病病的严重程度与尿酸水平呈负相关，与同型半胱氨酸成正相关。同型半胱氨酸可能成为PD合并便秘的新的生物标志物。</p></sec><sec id="s2"><title>关键词</title><p>帕金森病，便秘，尿酸，同型半胱氨酸，生物标志物</p></sec><sec id="s3"><title>Analysis of Serum Uric Acid and Homocysteine Levels in Parkinson’s Patients with Constipation</title><p>Rui Qiu, Shanshan Ye, Xuening Li, Zhongnan Hao, Aijun Ma</p><p>The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p>Received: Feb. 17<sup>th</sup>, 2021; accepted: Mar. 5<sup>th</sup>, 2021; published: Mar. 22<sup>nd</sup>, 2021</p><p><img src="//html.hanspub.org/file/49-1572027x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To study the relationship between serum uric acid (UA), homocysteine (Hcy) and Parkinson’s disease (PD) combined with constipation. Methods: 109 cases of Parkinson’s disease who were treated in the outpatient clinic of Qingdao University Hospital from May 2020 to January 2021 were selected as the PD group. According to the patient’s current medical history, the PD group was divided into the constipation group and the non-constipation group. And 105 healthy people were selected in our hospital during the same period as the control group. 1) Analyze the correlation between blood uric acid, blood homocysteine levels and Parkinson’s disease. 2) Analyze the possible relationship between these two serum indexes in Parkinson’s disease patients with RBD. Results: 1) Compared with the normal control group, the UA and Hcy levels of the two groups were different in the PD group, and the difference was statistically significant (P &lt; 0.05); 2) There was no significant difference in the UA level between the constipation group and the non-constipation group. The Hcy level of the constipation group was higher than that of the non-constipation group, and the difference was statistically significant (P &lt; 0.05); 3) The severity of Parkinson’s disease was negatively correlated with the level of uric acid, and positively correlated with homocysteine. There was statistical significance (P &lt; 0.05); 4) The diagnostic efficiency of Hcy for constipation is: (AUC = 0.661, 95% CI = 0.556~0.767, P &lt; 0.05), and its sensitivity and specificity are 58.3% and 75.4%, respectively. Conclusion: Serum uric acid and isotype cysteine have a certain correlation with the onset of Parkinson’s disease, and the severity of Parkinson’s disease is negatively correlated with uric acid levels and positively correlated with homocysteine. Homocysteine may become a new biomarker of PD with constipation.</p><p>Keywords:Parkinson’s Disease, Constipation, Uric Acid, Homocysteine, Biomarkers</p><disp-formula id="hanspub.41074-formula26"><graphic xlink:href="//html.hanspub.org/file/49-1572027x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/49-1572027x7_hanspub.png" /> <img src="//html.hanspub.org/file/49-1572027x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>帕金森病是世界第二大慢性神经退行性疾病，其发病率仅次于阿尔兹海默症，其主要的临床表现为静息性震颤、运动迟缓、肌强直和姿势不稳，PD的病理表现是中脑黑质中多巴胺能神经元的变性丢失，导致纹状体中多巴胺水平降低以及路易小体(Lewy body)的聚集。除运动症状外，PD患者经常伴有非运动症状，如：睡眠障碍、认知障碍、心血管功能障碍、胃肠道功能障碍等 [<xref ref-type="bibr" rid="hanspub.41074-ref1">1</xref>]，胃肠道功能紊乱是最常见的PD非运动症状，而胃肠道功能紊乱中80%~90%表现为便秘 [<xref ref-type="bibr" rid="hanspub.41074-ref2">2</xref>]，为帕金森病下消化道功能障碍最为突出与致残表现之一。目前有多种机制与PD的发病有关，而导致黑质多巴胺能神经元变性丢失的关键是氧化应激作用 [<xref ref-type="bibr" rid="hanspub.41074-ref3">3</xref>]，尿酸(Uric acid)为体内抗氧化剂，具有清除过氧自由基、羟基自由基和过氧亚硝酸基的作用，多个研究表明 [<xref ref-type="bibr" rid="hanspub.41074-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.41074-ref5">5</xref>]，PD病人血尿酸水平低于正常人群。高同型半胱氨酸(Hcy)使儿茶酚胺羟基化，其衍生物可能对神经元造成损害，导致多巴胺能神经元减少黑质细胞凋亡，可能对PD的发病产生影响 [<xref ref-type="bibr" rid="hanspub.41074-ref6">6</xref>]。暂未有人研究UA、Hcy水平与便秘的关系，我们将进行进一步研究探讨。</p></sec><sec id="s6"><title>2. 对象与方法</title><sec id="s6_1"><title>2.1. 对象</title><p>纳入标准：研究对象取自2020年5月~2020年12月青岛大学附属医院帕金森病专病门诊就诊的PD患者109例，均符合《中国帕金森病的诊断标准》(2016版)确诊的帕金森病诊断标准 [<xref ref-type="bibr" rid="hanspub.41074-ref7">7</xref>]，按是否便秘分为便秘组及无便秘组。1) PD-便秘组：48例，平均年龄为(64.0 &#177; 9.5)岁；病程0.5~14年，平均(3.87 &#177; 3.16)年。2) PD-非便秘组：61例，年龄42~82岁，平均(63.1 &#177; 9.5)岁；病程0.5~10.5年，平均(2.37 &#177; 1.91)年。并选取同一时段健康体检者105名，设为对照组。本项目研究取得我院伦理委员会的审批。</p><p>排除标准：排除既往痛风患者和正在服用影响尿酸代谢药物者；排除有严重的心、肺及肝肾疾病患者；排除有器质性胃肠道病变患者；帕金森综合症和帕金森叠加综合症患者。</p></sec><sec id="s6_2"><title>2.2. 方法</title><sec id="s6_2_1"><title>2.2.1. 临床资料的收集</title><p>收集纳入组的研究对象临床资料，包括年龄、性别、高血压、糖尿病、冠心病、吸烟史、饮酒史、服用药物史，病程等。见表1。</p></sec><sec id="s6_2_2"><title>2.2.2. 血液样本的采集</title><p>相关指标检测 采集所有研究对象空腹 &gt; 8 h的静脉血。应用贝克曼库尔特-AU5800全自动生化分析仪检测血清尿酸(serum uric acid, UA)、同型半胱氨酸(Hyperhomocysteinemia, Hcy)。</p></sec></sec><sec id="s6_3"><title>2.3. 统计方法</title><p>采用spss23.0软件进行数据分析，计量资料用均数&#177;标准差(x &#177; s)表示，数据为正态分布采用t检验进行比较，非正态性采用Mann-Whiney U检验；计数资料用百分数[n (%)]表示，用χ<sup>2</sup>检验进行比较，用Kolmogorov-Smirnov检验正态性，以P &lt; 0.05有统计学差异。多因素分析应用二元Logistic回归。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 临床资料的比较</title><p>两组临床资料对比，无统计学差异，有可比性。见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of clinical data between the two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >比较项目</th><th align="center" valign="middle" >PD组</th><th align="center" valign="middle" >正常对照组</th><th align="center" valign="middle" >χ<sup>2</sup>/t</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >66.34 &#177; 9.858</td><td align="center" valign="middle" >64.74 &#177; 9.994</td><td align="center" valign="middle" >1.176</td><td align="center" valign="middle" >0.241</td></tr><tr><td align="center" valign="middle" >男[n (%)]</td><td align="center" valign="middle" >48 (44.0)</td><td align="center" valign="middle" >57 (54.3)</td><td align="center" valign="middle" >2.248</td><td align="center" valign="middle" >0.134</td></tr><tr><td align="center" valign="middle" >高血压[n (%)]</td><td align="center" valign="middle" >43 (39.4)</td><td align="center" valign="middle" >48 (45.7)</td><td align="center" valign="middle" >0.859</td><td align="center" valign="middle" >0.354</td></tr><tr><td align="center" valign="middle" >冠心病[n (%)]</td><td align="center" valign="middle" >18 (16.5)</td><td align="center" valign="middle" >9 (8.6)</td><td align="center" valign="middle" >3.060</td><td align="center" valign="middle" >0.080</td></tr><tr><td align="center" valign="middle" >糖尿病[n (%)]</td><td align="center" valign="middle" >14 (12.8)</td><td align="center" valign="middle" >8 (7.6)</td><td align="center" valign="middle" >1.583</td><td align="center" valign="middle" >0.208</td></tr><tr><td align="center" valign="middle" >吸烟史[n (%)]</td><td align="center" valign="middle" >13 (11.9)</td><td align="center" valign="middle" >19 (18.1)</td><td align="center" valign="middle" >1.600</td><td align="center" valign="middle" >0.206</td></tr><tr><td align="center" valign="middle" >饮酒史[n (%)]</td><td align="center" valign="middle" >8 (7.3)</td><td align="center" valign="middle" >16 (15.2)</td><td align="center" valign="middle" >3.351</td><td align="center" valign="middle" >0.067</td></tr></tbody></table></table-wrap><p>表1. 两组临床资料比较</p></sec><sec id="s7_2"><title>3.2. 两组UA及Hcy水平比较</title><p>PD组与正常对照组相比较，两组PD组UA水平低于对照组，差异具有统计学意义(P &lt; 0.05)。见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of UA and Hcy levels between the two groups (x &#177; s</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >UA (μmol/L)</th><th align="center" valign="middle" >Hcy (μmol/L)</th></tr></thead><tr><td align="center" valign="middle" >PD组(N = 123)</td><td align="center" valign="middle" >291.44 &#177; 76.57</td><td align="center" valign="middle" >13.66 &#177; 3.33</td></tr><tr><td align="center" valign="middle" >对照组(N = 121)</td><td align="center" valign="middle" >343.63 &#177; 76.68</td><td align="center" valign="middle" >11.11 &#177; 2.53</td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle" >−4.981</td><td align="center" valign="middle" >6.37</td></tr><tr><td align="center" valign="middle" >p</td><td align="center" valign="middle" >0.00</td><td align="center" valign="middle" >0.00</td></tr></tbody></table></table-wrap><p>表2. 两组UA、Hcy水平比较(x &#177; s)</p></sec><sec id="s7_3"><title>3.3. PD-便秘组与PD-非便秘组UA、Hcy水平比较</title><p>便秘组与非便秘组UA、Hcy水平比较，两组UA水平比较差异无统计学意义，而便秘组Hcy高于非便秘组，差异有统计学意义。见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of uric acid and homocysteine levels between PD-constipation group and PD-non-constipation grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >UA (μmol/L)</th><th align="center" valign="middle" >Hcy (μmol/L)</th></tr></thead><tr><td align="center" valign="middle" >便秘组(N = 54)</td><td align="center" valign="middle" >296.23 &#177; 72.07</td><td align="center" valign="middle" >14.79 &#177; 3.66</td></tr><tr><td align="center" valign="middle" >非便秘组(N = 69)</td><td align="center" valign="middle" >287.67 &#177; 80.32</td><td align="center" valign="middle" >12.77 &#177; 2.69</td></tr><tr><td align="center" valign="middle" >t/Z</td><td align="center" valign="middle" >0.577</td><td align="center" valign="middle" >3.206</td></tr><tr><td align="center" valign="middle" >p</td><td align="center" valign="middle" >0.565</td><td align="center" valign="middle" >0.002</td></tr></tbody></table></table-wrap><p>表3. PD-便秘组与PD-非便秘组UA、Hcy水平比较(x &#177; s)</p></sec><sec id="s7_4"><title>3.4. 血清UA、Hcy与PD患者的相关性分析</title><p>当控制年龄、性别、高血压病史、高血压病史、冠心病病史、吸烟饮酒史等因素，发现PD组严重程度与UA (OR: 0.989, 95% CI: 0.984~0.994, P = 0.000)、Hcy (OR: 1.511, 95% CI: 1.306~1.747, P = 0.000)都相关。其中UA与PD之间存在负相关，而Hcy与PD存在正相关。</p></sec><sec id="s7_5"><title>3.5. 便秘组和非便秘组之间的血清Hcy水平的ROC曲线</title><p>构建比较便秘组和非便秘组之间的血清Hcy水平的受试者工作特征曲线(receiver operating characteristic curve，ROC曲线，ROC曲线结果显示：Hcy的曲线下面积为：(AUC = 0.661, 95% CI = 0.556~0.767, p &lt; 0.05)，其灵敏性和特异性分别为：58.3%，75.4%。见图1。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>帕金森病常合并多种非运动症状的发生，包括自主神经功能异常、精神神经异常、感觉异常等 [<xref ref-type="bibr" rid="hanspub.41074-ref8">8</xref>]，而便秘是PD患者最常见的自主神经功能症状之一，可早于PD的运动症状10~20年出现 [<xref ref-type="bibr" rid="hanspub.41074-ref9">9</xref>]。不同的研究表明约20%~89%的帕金森病患者都伴有便秘，且伴随病程的进展，其发病率也逐渐增加 [<xref ref-type="bibr" rid="hanspub.41074-ref10">10</xref>]。PD病人便秘的发生可能与结肠运输延迟、直肠肛门运输障碍、抗PD药物，肠道菌群失调等多种因素相关 [<xref ref-type="bibr" rid="hanspub.41074-ref11">11</xref>]。胃肠道功能的控制受多个系统复杂控制，但大部分是由自主神经系统和肠神经系统支配，肠神经系统中包含最多的神经元是胆碱能神经元，而PD患者肠神经系统多巴胺神经元发生变性坏死，可能是引起便秘的原因之一 [<xref ref-type="bibr" rid="hanspub.41074-ref12">12</xref>]。也有研究表明，便秘的原因也可能是由肠肌间神经元丢失 [<xref ref-type="bibr" rid="hanspub.41074-ref13">13</xref>]。</p><p>图1. 便秘组和非便秘组之间的血清Hcy水平的ROC曲线</p><p>尿酸(UA)可能是一种潜在的神经保护剂。有研究表明低水平的血UA与发生多种神经退行性疾病(包括PD)的风险增加有关 [<xref ref-type="bibr" rid="hanspub.41074-ref14">14</xref>]。此外，有研究已经确定血UA水平较低的PD患者恶化速度更快 [<xref ref-type="bibr" rid="hanspub.41074-ref15">15</xref>]。本研究表明，PD组血尿酸明显低于正常对照组，低UA可能会使患帕金森病的风险增高，这与此前大多数学者的研究结果是一致的。UA具有对帕金森病的天然神经保护作用。在细胞PD模型中，星形胶质细胞内的尿酸可预防多巴胺能细胞的死亡和氧化、线粒体毒素诱导的萎缩 [<xref ref-type="bibr" rid="hanspub.41074-ref16">16</xref>]。并且UA具有铁螯合特性，毒性铁可促进α-突触核蛋白错误折叠和聚集，导致PD发生。UA的铁螯合性表现在通过与Fe<sup>3+</sup>形成稳定的配合物，并降低Fe<sup>3+</sup>的氧化潜力 [<xref ref-type="bibr" rid="hanspub.41074-ref17">17</xref>]。我们首次研究了在帕金森病合并便秘中UA的表达水平。结果显示而UA在两组间差异无统计学意义。</p><p>同型半胱氨酸(Hcy)是一种含硫氨基酸，是蛋氨酸代谢的中间产物，其主要参与体内甲基化反应和能量代谢。高Hcy会促使氧自由基和过氧化氢的生成，使体内ROS、RNS等物质增多，会引起脑组织的氧化受损，脑黑质受损则会出现震颤等运动症状 [<xref ref-type="bibr" rid="hanspub.41074-ref18">18</xref>]。本次研究我们发现Hcy在PD组中高表达，且与帕金森病的严重程度成正相关，这与之前的研究结果是相符的 [<xref ref-type="bibr" rid="hanspub.41074-ref19">19</xref>]。高Hcy可从与动脉粥样硬化(AS)相互促进、促使氧自由基和过氧化氢生成，引起血管内皮损伤及脑组织氧化损伤、诱导神经元凋亡、影响神经传导功能等方面导致PD病人的认知功能下降 [<xref ref-type="bibr" rid="hanspub.41074-ref18">18</xref>]。我们的研究发现Hcy在PD-便秘组病人中高表达，差异具有统计学意义，但其中的机制我们并不清楚，我们推断高Hcy诱导神经元凋亡、影响神经传导功能，不仅在中枢神经系统中发挥作用 [<xref ref-type="bibr" rid="hanspub.41074-ref18">18</xref>]，也可能对PD患者肠神经系统多巴胺神经元产生影响。我们对便秘组和非便秘组之间的血清Hcy水平构建ROC曲线可知，Hcy对便秘的诊断效能并不高(AUC = 0.661)，可能由于我们的PD患者样本数量有限，与大样本人群的统计结果存在偏差，但仍需进一步扩大样本研究提供证据。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，血清UA、Hcy与PD的发病有一定的相关性，UA与PD严重程度之间存在负相关，而Hcy与PD严重程度存在正相关。Hcy可能成为PD合并便秘的新的标志物，未来需要进一步研究和探讨。</p></sec><sec id="s10"><title>文章引用</title><p>邱 蕊,叶珊珊,李雪宁,郝中楠,马爱军. 合并便秘的帕金森病人血清尿酸、同型半胱氨酸水平分析Analysis of Serum Uric Acid and Homocysteine Levels in Parkinson’s Patients with Constipation[J]. 临床医学进展, 2021, 11(03): 1154-1159. https://doi.org/10.12677/ACM.2021.113166</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41074-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Weerkamp, J., Tissingh, G., Poels, P.J., Zuidema, S.U., Munneke, M., Koopmans, R.T.C.M., et al. (2013) Nonmotorsymptoms in Nursing Home Residents with Parkinson’s Disease: Prevalence and Effect on Quality of Life. Journal of the American Geriatrics Society, 7, 1714-1721. &lt;br&gt;https://doi.org/10.1111/jgs.12458</mixed-citation></ref><ref id="hanspub.41074-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Pfeiffer, R.F. (2003) Gastrointestinal Dysfunction in Parkinson’s Disease. Lancet Neurology, 2, 107-116. 
&lt;br&gt;https://doi.org/10.1016/S1474-4422(03)00307-7</mixed-citation></ref><ref id="hanspub.41074-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, T., Sun, Q. and Chen, S. (2016) Oxidative Stress: A Major Pathogenesis and Potential Therapeutic Target of Antioxidative Agents in Parkinson’s Disease and Alzheimer’s Disease. Progress in Neurobiology, 147, 1-19. 
&lt;br&gt;https://doi.org/10.1016/j.pneurobio.2016.07.005</mixed-citation></ref><ref id="hanspub.41074-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">de Lau, L.M., Koudstaal, P.J., Hofman, A. and Breteler, M.M.B. (2005) Serum Uric Acid Levels and the Risk of Parkinson Disease. Annals Neurology, 58, 797-800. &lt;br&gt;https://doi.org/10.1002/ana.20663</mixed-citation></ref><ref id="hanspub.41074-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Shen, L. and Ji, H.F. (2013) Low Uric Acid Levels in Patients with Parkinson’s Disease: Evidence from Meta-Analysis. BMJ Open, 3, e003620. &lt;br&gt;https://doi.org/10.1136/bmjopen-2013-003620</mixed-citation></ref><ref id="hanspub.41074-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">黄碧霞, 郭少勇. 老年帕金森病患者血清同型半胱氨酸及血尿酸水平与认知功能障碍的相关性分析[J]. 中国医师杂志, 2020, 22(3): 443-445.</mixed-citation></ref><ref id="hanspub.41074-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会神经病学分会帕金森病及运动障碍学组. 中国帕金森病的诊断标准(2016版)[J]. 中华神经科杂志, 2016, 49(4): 268-271.</mixed-citation></ref><ref id="hanspub.41074-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">李二凤, 刘佳佳, 于翠玉, 华平, 赵燕燕, 刘卫国. 帕金森病患者运动和非运动症状的性别差异[J]. 临床神经病学杂志, 2014, 27(1): 8-11.</mixed-citation></ref><ref id="hanspub.41074-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Gage, H., Kaye, J., Kimber, A., Storey, L., Egan, M., Qiao, Y., et al. (2011) Correlates of Constipation in People with Parkinson’s. Parkinsonism &amp; Related Disorders, 17, 106-111. &lt;br&gt;https://doi.org/10.1016/j.parkreldis.2010.11.003</mixed-citation></ref><ref id="hanspub.41074-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Pfeiffer, R.F. (2011) Gastrointestinal Dysfunction in Parkinson’s Disease. Parkinsonism &amp; Related Disorders, 17, 10-15. &lt;br&gt;https://doi.org/10.1016/j.parkreldis.2010.08.003</mixed-citation></ref><ref id="hanspub.41074-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">曾奇, 刘智斌, 王渊, 刁秀芸, 郭萌. 帕金森病便秘的研究进展[J]. 辽宁中医药大学学报, 2020, 22(8): 40-44.</mixed-citation></ref><ref id="hanspub.41074-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">施君杰, 干静, 刘振国. 帕金森病便秘机制的研究进展[J]. 中国临床神经科学, 2015, 23(6): 711-714.</mixed-citation></ref><ref id="hanspub.41074-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Wedel, T., Spiegler, J., Soellner, S., Roblick, U.J., Schiedeck, T.H.K., Bruch, H.-P., et al. (2002) Enteric Nerves and Interstitial Cells of Cajal Are Altered in Patients with Slow Transit Constipation and Megacolon. Gastroenterology, 9, 1459-1467. &lt;br&gt;https://doi.org/10.1053/gast.2002.36600</mixed-citation></ref><ref id="hanspub.41074-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Schlesinger, I. and Schlesinger, N. (2008) Uric Acid in Parkinson’s Disease. Movement Disorders, 23, 1653-1657. 
&lt;br&gt;https://doi.org/10.1002/mds.22139</mixed-citation></ref><ref id="hanspub.41074-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Schwarzschild, M.A., Schwid, S.R., Marek, K., Watts, A., Lang, A.E., Oakes, D., et al. (2008) Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease. Archives of Neurology, 65, 716-723. 
&lt;br&gt;https://doi.org/10.1001/archneur.2008.65.6.nct70003</mixed-citation></ref><ref id="hanspub.41074-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Cipriani, S., Desjardins, C.A., Burdett, T.C., Xu, Y., Xu, K. and Schwarzschild, M.A. (2012) Urate and Its Transgenic Depletion Modulate Neuronal Vulnerability in a Cellular Model of Parkinson’s Disease. PLoS ONE, 7, e37331. 
&lt;br&gt;https://doi.org/10.1371/journal.pone.0037331</mixed-citation></ref><ref id="hanspub.41074-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Dusek, P., Schneider, S.A. and Aaseth, J. (2016) Iron Chelation in the Treatment of Neurodegenerative Diseases. Journal of Trace Elements in Medicine and Biology, 38, 81-92. &lt;br&gt;https://doi.org/10.1016/j.jtemb.2016.03.010</mixed-citation></ref><ref id="hanspub.41074-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">段盼, 罗华. 高同型半胱氨酸与帕金森病认知功能障碍的关系及机制[J]. 实用心脑肺血管病杂志, 2013, 21(4): 167-169.</mixed-citation></ref><ref id="hanspub.41074-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">李希芝, 马贺, 傅勇, 刘庆新. 帕金森病及帕金森病痴呆患者血浆Hcy及催乳素水平的变化及意义[J]. 中国老年学杂志, 2016, 36(4): 841-842.</mixed-citation></ref></ref-list></back></article>